Privium Fund Management B.V. Takes Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• Privium Fund Management B.V. has acquired 10,987 shares of BioNTech SE, valued at approximately $1.18 million, making it the firm's 29th largest holding.
• Several institutional investors, including DekaBank and TD Asset Management, have significantly increased their positions in BioNTech, indicating growing interest in the company.
• Analysts have set various price targets for BioNTech, with a consensus rating of Moderate Buy and an average target price of $134.32, amidst mixed ratings from different brokerages.

Privium Fund Management B.V. purchased a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,987 shares of the company's stock, valued at approximately $1,181,000. BioNTech makes up approximately 0.3% of Privium Fund Management B.V.'s holdings, making the stock its 29th biggest holding.

Several other institutional investors have also recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale grew its holdings in BioNTech by 16.9% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company's stock worth $51,764,000 after acquiring an additional 69,500 shares in the last quarter. Allianz Asset Management GmbH lifted its position in shares of BioNTech by 2.3% during the second quarter. Allianz Asset Management GmbH now owns 123,495 shares of the company's stock worth $13,149,000 after purchasing an additional 2,815 shares during the last quarter. TD Asset Management Inc lifted its position in shares of BioNTech by 1,417.6% during the second quarter. TD Asset Management Inc now owns 173,795 shares of the company's stock worth $18,513,000 after purchasing an additional 162,343 shares during the last quarter. LRI Investments LLC increased its holdings in BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after buying an additional 312 shares during the last quarter. Finally, Aberdeen Group plc raised its stake in BioNTech by 87.2% during the second quarter. Aberdeen Group plc now owns 721,928 shares of the company's stock valued at $76,864,000 after buying an additional 336,260 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BNTX. JPMorgan Chase & Co. boosted their price target on BioNTech from $116.00 to $121.00 and gave the company a "neutral" rating in a report on Monday, September 22nd. Morgan Stanley lowered their target price on shares of BioNTech from $133.00 to $131.00 and set an "overweight" rating for the company in a research note on Friday, October 10th. HC Wainwright reissued a "buy" rating and set a $136.00 target price on shares of BioNTech in a report on Monday, September 8th. Bank of America lifted their price target on shares of BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a research note on Tuesday, October 14th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and a consensus price target of $134.32.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $107.95 on Tuesday. The firm's 50 day moving average is $103.73 and its two-hundred day moving average is $104.18. The firm has a market capitalization of $25.95 billion, a P/E ratio of -67.47 and a beta of 1.45. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business's quarterly revenue was up 102.6% compared to the same quarter last year. During the same period last year, the company earned ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. Analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.